Media Contact

Successful lactation studies require careful consideration of both science and participant experience. ICON's mother- and infant-centric approach combines flexible scheduling, home visit options, specialised support, and...

The conversation around AI in healthcare is changing. The question is no longer whether AI can support clinical decision-making. The question is how regulators, developers and healthcare systems can ensure these technol...

Obesity studies face a growing paradox: demand for trial participation has never been higher, yet attrition remains one of the biggest threats to study success. As therapies become increasingly differentiated, retention...

The shift from fragmented health data systems to a harmonised European framework has significant implications for life sciences organisations. ICON specialists examine the operational, technical and methodological chang...

PubsHub Knowledge Manager is an enterprise-wide document repository solution. Knowledge Manager is ideal for teams needing fast, efficient and secure access to scientific content. Empower your team to work better. Learn ...

What does regulatory readiness look like for the next generation of AI-enabled medical devices? As AI evolves from detection and triage to diagnosis and treatment planning, regulators are raising expectations around: -...

Healthcare is moving towards a future where AI-enabled technologies do more than identify disease. Increasingly, they are expected to support complex clinical decisions that can directly influence patient care. That sh...

The RACE Act changed pediatric oncology in the US. The EMA’s proposed MoA PIP requirements could do the same in Europe. So what does this mean for sponsors? ICON’s Regulatory Affairs (Graham Bell) and Pediatrics (Jacqu...

A standout achievement for ICON was earning EcoVadis Platinum Medal status with a score of 87/100, placing ICON in the top 1% of all organisations assessed. This recognition reflects our continued focus on environmental...

Decentralised clinical trials continue to evolve and ICH GCP E6(R3) Annex 2 provides greater clarity on how they can be implemented within a robust quality framework. In Clinical Trials Arena, ICON's Wendy DeSpain highl...

What comes next for pivotal trial design in cell and gene therapies? As new and next generation therapies emerge, sponsors face increasingly complex questions around comparator selection, study feasibility and evidence g...

The PPWR introduces a long-term compliance framework that will impact medical device packaging well beyond 2026. Speaking with Medtech Insight, ICON regulatory SMEs Claudia Anzaldo and Véronique Boscher highlight the im...